17- N,N- diethylcarbamoyl- 4- methyl- 4- azaandrostane- 3- one (DMAA)

inhibitor of testosterone 5-alpha reductase, receptor binding & nuclear uptake of androgens in the prostate

Also Known As:

DMAA; 17 beta-N,N-diethylcarbamoyl-4-methyl-4-aza-5 alpha-androstan-3-one; 17-N,N-diethyl-4-methyl-3-oxo-4-azaandrostane-17-carboxamide; 4MA compound; 4-Azaandrostane-17-carboxamide, N,N-diethyl-4-methyl-3-oxo-, (5alpha,17beta)-

Networked: 155 relevant articles (11 outcomes, 9 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Dammerer, Dietmar: 7 articles (07/2022 - 01/2019)
2.	Kaufmann, Gerhard: 7 articles (07/2022 - 01/2019)
3.	Braito, Matthias: 6 articles (07/2022 - 01/2019)
4.	Nery, Caio: 4 articles (01/2022 - 09/2002)
5.	Putzer, David: 3 articles (07/2022 - 06/2019)
6.	Ulmer, Hanno: 3 articles (07/2022 - 06/2019)
7.	Biz, Carlo: 3 articles (04/2021 - 07/2015)
8.	Hofer, Philipp: 3 articles (06/2020 - 06/2019)
9.	Li, Yi: 3 articles (01/2020 - 10/2019)
10.	Liu, Cheng: 3 articles (01/2020 - 10/2019)

Related Diseases

1.	Hallux Valgus 12/01/2020 - "Evaluation of standard radiographic parameters (hallux-valgus angle [HVA], intermetatarsal angle 1-2 [IMA 1-2], distal metatarsal articular angle [DMAA], tibial sesamoid position [TSP]) showed significant improvement postoperatively. " 04/01/2015 - "There was a statistically significant improvement in the inter-metatarsal angle (IMA, p = 0.0003), hallux valgus angle (HVA, p < 0.0001) and distal metatarsal articular angle (DMAA, p = 0.019). " 01/01/2008 - "Radiological assessment revealed a significant improvement (p<0.001) of the hallux valgus angle (mean reduction 17.4 degrees), the intermetatarsal angle (mean reduction 5.8 degrees), the medial sesamoid position (14% of the feet were grade 1 or less preoperatively and this rate increased to 84% at follow-up) and the DMAA (mean reduction 9 degrees). " 05/24/2022 - "Thus, we investigated the efficacy of the modified Lapidus procedure, a triplanar correction, in correcting the DMAA in hallux valgus surgery. " 08/01/2012 - "Hallux valgus angle (HVA), IMA and DMAA corrections improved with the formula (p = 0.036, p = 0.049, and p = 0.006, respectively). "
2.	Congenital Abnormalities (Deformity) 12/01/2017 - "This study aims to illustrate the results of percutaneous forefoot surgery (PFS) for correction of HV deformity without DMAA correction. " 11/01/2021 - "The HVA, IMA, distal metatarsal articular angle (DMAA), relative length of the second metatarsal, medial sesamoid position, and Meary's angle to evaluate the degree of deformity correction and its maintenance were measured pre-operatively and at the final follow-up. " 03/01/2019 - "Preoperative deformity, in terms of IMA, HVA, DMAA, and sesamoid position, correlated with the loss of correction and could be assessed preoperatively for HVA and IMA. " 11/01/2018 - "Angular deformity (HVA, IMA, and DMAA) showed low correlation with postsurgery foot width. " 07/01/2015 - "Recurrence was associated with greater preoperative deformity and an increased preoperative DMAA. "
3.	Bunion 01/01/2023 - "Nearly all juvenile bunions have an elevated DMAA and a congruent joint. " 09/01/1998 - "We have demonstrated this procedure to be useful in the treatment of symptomatic bunion deformities with an increased DMAA." 01/01/2023 - "We believe that the presence of elevated DMAA is the defining factor that differentiates the juvenile bunion from the deformity typically seen in adults. "
4.	Dementia (Dementias) 10/18/2004 - "Trials were identified from a search of the Trial-based Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 7 April 2004 using the terms: memantin, namenda, ebixa, axura, D-145, DMAA, DRG-0267. " 01/01/2003 - "Trials were identified from a search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 15 April 2003 using the terms: memantin, D-145, DMAA, DRG-0267. " 01/01/2003 - "Trials were identified from a search of the Trial-based Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 9 October 2002 using the terms: memantin, D-145, DMAA, DRG-0267. "
5.	Carcinogenesis 12/11/1998 - "These results indicate that DMAA has promoting effects on urinary bladder carcinogenesis even in NBR rats, so its effects are not dependent on the presence of alpha2u-globulin." 08/01/2004 - "In conclusion, DMAA exposure causes oxidative stress, DNA damage and specific induction of apoptosis in target organs of arsenic carcinogenesis, which may be attributable to the mechanism(s) of arsenic-induced carcinogenesis in rodents. " 03/13/1998 - "These results are consistent with the epidemiological studies on the pulmonary carcinogenesis of arsenics and suggest that DMAA alone can act as a carcinogen in mice." 12/01/1997 - "These results indicate that DMAA has the potential to promote rat liver carcinogenesis, possibly via a mechanism involving stimulation of cell proliferation and DNA damage caused by oxygen radicals." 12/01/1997 - "In the present study, we investigated the dose-dependent promotion potential of dimethylarsinic acid (DMAA), a major metabolite of inorganic arsenicals in mammals, in a rat liver carcinogenesis model. "

Related Drugs and Biologics

1.	Memantine (Namenda)
2.	polyterephthalic acid anhydride
3.	Cacodylic Acid (Cacodylate)
4.	Arsenicals (Arsenic Compounds)
5.	Glucose (Dextrose)
6.	1,3-dimethylamylamine
7.	Fluorometholone (FML)
8.	Arsenic
9.	Sympathomimetics (Sympathomimetic Amines)
10.	Insulin (Novolin)

Related Therapies and Procedures

1.	Osteotomy
2.	Therapeutics
3.	Continuity of Patient Care
4.	Communication Aids for Disabled (TDD)
5.	Contraindications